Xyrem Settlement Gets Green Light

Law360, New York (July 13, 2007, 12:00 AM EDT) -- A federal judge on Friday approved Jazz Pharmaceuticals Inc.'s $20 million settlement with the federal government over an investigation into the promotion of Xyrem, a narcolepsy treatment containing oft-abused GHB, by Orphan Medical Inc., now a subsidiary of Jazz.

GHB, the popular name for gamma-hydroxybutyrate, is a powerful and almost immediate central nervous system depressant that is often illegally used for recreation. The Health and Human Services Department has classified it as a date rape drug.

Jazz' settlement figure, approved by Judge Eric Vitaliano of the...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.